The use of fenofibrate in the management of patients with diabetic retinopathy: an evidence-based review.

Abstract

BACKGROUND:

Diabetic retinopathy is a significant cause of vision impairment, especially affecting those of working age. There are two large, randomised controlled trials examining the effect of fenofibrate on diabetic retinopathy.

OBJECTIVE:

We summarise their findings, and report on the available safety data.

DISCUSSION:

The FIELD study reported that patients treated with fenofibrate had a statistically significant relative risk reduction in the need for laser treatment for maculopathy and proliferative retinopathy. The ACCORD-Eye study reported a statistically significant reduction in diabetic retinopathy progression in patients treated with fenofibrate and statin combination therapy compared to statin therapy alone. There is firm evidence that fenofibrate slows the progression of diabetic retinopathy and the need for more invasive treatment modalities in patients with type 2 diabetes, especially those with pre-existing retinopathy. In October 2013, Australia became the first country in the world to approve the use of this medication for this specific indication.

• Authors: Neil Sharma, Ju-Lee Ooi, Jong Ong, Douglas Newman
• Journal: Australian family physician (Aust Fam Physician) Vol. 44 Issue 6 Pg. 367-70 (Jun 2015) ISSN: 0300-8495 [Print] Australia
• PMID: 26209985 (Publication Type: Journal Article, Review)

Chemical References

• PPAR alpha
• Fenofibrate

Topics

• Australia
• Diabetes Mellitus, Type 2 (complications)
• Diabetic Retinopathy (drug therapy)
• Disease Progression
• Fenofibrate (adverse effects, therapeutic use)
• Humans
• PPAR alpha (adverse effects, agonists)